Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX- 497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 859-866

  Markland, W ^a   Mcquaid, T J ^a   Jain, J ^a   Kwong, A D ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ENZYME INHIBITOR; GUANOSINE; INOSINATE DEHYDROGENASE; MERIMEPODIB; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CELL VIABILITY; COXSACKIE VIRUS B3; CYTOMEGALOVIRUS; CYTOTOXICITY; DENGUE VIRUS; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS 1; INFLUENZA VIRUS; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CARBAMATES; CATTLE; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; ELECTROPHORESIS; ENZYME INHIBITORS; FIBROBLASTS; GUANOSINE; HUMANS; IMP DEHYDROGENASE; INTERFERON-ALPHA; MICE; MOLECULAR WEIGHT; PHENYLUREA COMPOUNDS; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VIRUSES;

EID: 0034102651     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.859-866.2000     Document Type: Article

References (37)

1. Allison, A. C., T. Hovi, R. W. E. Watts, and A. D. B. Webster. 1977. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found. Symp. 48:207-224.
2. Cassidy, L. F., and J. L. Patterson. 1989. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob. Agents Chemother. 33:2009-2011.
3. Colby, T. D., K. Vanderveen, M. D. Strickler, G. D. Markham, and B. M. Goldstein. 1999. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. USA 96:3531-3536.
4. De Clercq, E. 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact, p. 1-55. Academic Press, Inc., New York, N.Y.
5. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpes viruses and retroviruses. Rev. Med. Virol. 5:149-164.
6. De Clercq, E., M. Cools, J. Balzarini, R. Snoeck, G. Andrei, M. Hosoya, S. Shigeta, T. Ueda, N. Minakawa, and A. Matsuda. 1991. Antiviral activities of 5-ethynl-1-β-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:679-684.
7. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcrip3 tion initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
8. Eriksson, B., B. Helgstrand, N. G. Johansson, A. Larsson, A. Misiorny, J. O. Noren, L. Phillipson, K. Stenberg, G. Stening, S. Stridh, and B. Oberg. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:946-951.
9. Fernandez-Larsson, R., K. O'Connell, E. Koumans, and J. L. Patterson. 1989. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob. Agents. Chemother. 33:1668-1673.
10. Gale, M., Jr., and M. G. Katze. 1998. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 78:29-46.
11. Gilbert, B. E., and V. Knight. 1986. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents and Chemother. 30:201-205.
12. Goswami, B. B., E. Borek, and O. K. Sharma. 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89:830-836.
13. Hartman, N. R., S. A. Gurpreet, D. A. Cooney, H. Mitsuya, S. Kageyama, A. Fridland, S. Broder, and D. G. Johns. 1991. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol. Pharmacol. 40:118-124.
14. Jaramillo, M. L., N. Abraham, and J. C. Bell. 1995 The interferon system: a review with emphasis on the role of PKR in growth control. Cancer Invest. 13:327-338.
15. Kobashigawa, J., L. Miller, D. Renlund, R. Mentzer, E. Alderman, R. Bourge, M. Costanzo, H. Eisen, G. Dureau, R. Ratkovec, M. Hummel, D. Ipe, J. Johnson, A. Keogh, R. Mamelok, D. Mancini, F. Smart, and H. Valantine. 1998. A randomized active-controlled trial of mycophenolate mofetil in heart transplants. Transplantation. 64:507-515.
16. Korba, B. F., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
17. Kornberg, A., and T. A. Baker. 1992. DNA replication, p. 53-100. W. H. Freeman & Co., New York, N.Y.
18. 17a. Lohmann, V. H. Overton, and R Bartenschlager. 1999. Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. J. Biol. Chem. 274:10807-10815.
19. Main, J., B. McCarron, and H. C. Thomas. 1998. Treatment of chronic viral hepatitis. Antivir. Chem. Chemother. 9:449-460.
20. Neyts, J., G. Andrei, and E. De Clercq. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpes activities of acyclovir, gancyclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42:216-222.
21. Ning, Q., D. Brown, J. Parodo, M. Cattral, R. Gorczynski, E. Cole, L. Fung, J. W. Ding, M. F. Liu, O. Rotstein, M. J. Phillips, and G. Levy. 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol. 22:3487-3493.
22. Prichard, M. N. and C. Shipman. 1992. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
23. Rankin, J. T., S. B. Eppes, J. B. Antczak, and W. K. Joklik. 1989. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168:147-158.
24. Scheidel, L. M., and V. Stollar. 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on sindbis virus map to the nonstructural protein nsP1. Virology 181:490-499.
25. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
26. Silverman Kitchin, J. E., M. Keltz Pomeranz, G. Pak, K. Washenik, and J. L. Shupack. 1997. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J. Am. Acad. Dermatol. 37:445-449.
27. Sintchak, M. D., M. A. Fleminh, O. Futer, S. A. Raybuck, S. P. Chambers, P. R. Caron, M. A. Murcko, and K. P. Wilson. 1996. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85:921-930.
28. Sintchak, M. D., M. C. Badia, O. Futer, and E. Nimmesgern. 1999. X-ray crystal structure of the antiviral drug ribavirin monophosphate bound to IMP dehydrogenase. Antivir. Res. 41:A56.
29. Smee, D. F., and J. W. Huggins. 1999. Mode of action of ribavirin against cowpox and monkeypox viruses. Antivir. Res. 41:A52.
30. Sollinger, H. W. 1995. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant. Proc. 28:24-29.
31. Tam, R. C., B. Pai, J. Bard, C. Lim, D. R. Averett, U. T. Phan, and T. Milovanovic. 1999. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30:376-382.
32. Toltzis, P, K. O'Connell, and J. L. Patterson. 1988. Effect of phosphorylated rihavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32:492-497.
33. Wedemeyer, H., W. H. Caselmann, and M. P. Manns. 1998. Combination therapy of chronic hepatitis C: an important step but not the final goal! J. Hepatol. 291010-1014.
34. Wray, S. K., B. E. Gilbert, and V. Knight. 1985. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antivir. Res. 5:39-48.
35. Wray, S. K., B. E. Gilbert, M. W. Noall, and V. Knight. 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antivir. Res. 5:29-37.
36. Wright, T., M. L. Shiffman, S. Knox, E. Ette, R. S. Kauffman, and J. Alam. 1999. Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C. Hepatology 30(Suppl.):122A.
37. Wu, J. C. 1994. Mycophenolate mofetil: molecular mechanisms of action. Perspect. Drug Disc. Design 2:185-204.